IL127714A - Use of Topiramate or its history for the preparation of a preparation for the treatment of disorders of bipolar manic depression - Google Patents

Use of Topiramate or its history for the preparation of a preparation for the treatment of disorders of bipolar manic depression

Info

Publication number
IL127714A
IL127714A IL12771497A IL12771497A IL127714A IL 127714 A IL127714 A IL 127714A IL 12771497 A IL12771497 A IL 12771497A IL 12771497 A IL12771497 A IL 12771497A IL 127714 A IL127714 A IL 127714A
Authority
IL
Israel
Prior art keywords
treatment
formula
compound
topiramate
alkyl
Prior art date
Application number
IL12771497A
Other languages
English (en)
Hebrew (he)
Other versions
IL127714A0 (en
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of IL127714A0 publication Critical patent/IL127714A0/xx
Publication of IL127714A publication Critical patent/IL127714A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04N—PICTORIAL COMMUNICATION, e.g. TELEVISION
    • H04N21/00—Selective content distribution, e.g. interactive television or video on demand [VOD]
    • H04N21/40—Client devices specifically adapted for the reception of or interaction with content, e.g. set-top-box [STB]; Operations thereof
    • H04N21/43—Processing of content or additional data, e.g. demultiplexing additional data from a digital video stream; Elementary client operations, e.g. monitoring of home network or synchronising decoder's clock; Client middleware
    • H04N21/442—Monitoring of processes or resources, e.g. detecting the failure of a recording device, monitoring the downstream bandwidth, the number of times a movie has been viewed, the storage space available from the internal hard disk
    • H04N21/44213—Monitoring of end-user related data
    • H04N21/44222—Analytics of user selections, e.g. selection of programs or purchase activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Social Psychology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Databases & Information Systems (AREA)
  • Multimedia (AREA)
  • Signal Processing (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL12771497A 1996-06-28 1997-06-24 Use of Topiramate or its history for the preparation of a preparation for the treatment of disorders of bipolar manic depression IL127714A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2085096P 1996-06-28 1996-06-28
US08/881,008 US5753693A (en) 1996-06-28 1997-06-23 Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder
PCT/US1997/010949 WO1998000123A1 (en) 1996-06-28 1997-06-24 Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of manic-depressive bipolar disorders

Publications (2)

Publication Number Publication Date
IL127714A0 IL127714A0 (en) 1999-10-28
IL127714A true IL127714A (en) 2004-08-31

Family

ID=26693960

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12771497A IL127714A (en) 1996-06-28 1997-06-24 Use of Topiramate or its history for the preparation of a preparation for the treatment of disorders of bipolar manic depression

Country Status (21)

Country Link
US (1) US5753693A (ru)
EP (1) EP0932398B1 (ru)
JP (1) JP2002515875A (ru)
KR (1) KR20000022233A (ru)
CN (1) CN1224350A (ru)
AP (1) AP1401A (ru)
AT (1) ATE330593T1 (ru)
AU (1) AU739363B2 (ru)
BR (1) BR9712783A (ru)
CA (1) CA2258895C (ru)
CZ (1) CZ297342B6 (ru)
DE (1) DE69736183T2 (ru)
ES (1) ES2267144T3 (ru)
HU (1) HUP0003381A3 (ru)
IL (1) IL127714A (ru)
NO (1) NO317641B1 (ru)
NZ (1) NZ333565A (ru)
RU (1) RU2185824C2 (ru)
SK (1) SK180498A3 (ru)
WO (1) WO1998000123A1 (ru)
ZA (1) ZA975773B (ru)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9915434A (pt) * 1998-11-17 2001-12-04 Ortho Mcneil Pharm Inc Derivados anticonvulsivos úteis no tratamento dedistúrbio de estresse pós-traumático
US20020006908A1 (en) * 1998-12-03 2002-01-17 Daniel P. Van Kammen Anticonvulsant derivatives useful in treating schizophrenia
JP2002536328A (ja) 1999-02-08 2002-10-29 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 自閉症の処置に有効な抗痙攣剤誘導体
DE60019904T2 (de) * 1999-02-24 2006-05-04 University Of Cincinnati, Cincinnati Verwendung von sulfamatderivaten zur behandlung von impulskontrollerkrankungen
US6583172B1 (en) 1999-04-08 2003-06-24 Richard P. Shank Anticonvulsant derivatives useful in treating chronic neurodegenerative disorders
US6420369B1 (en) 1999-05-24 2002-07-16 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating dementia
US7056890B2 (en) 1999-06-14 2006-06-06 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US7659256B2 (en) * 1999-06-14 2010-02-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US7553818B2 (en) * 1999-06-14 2009-06-30 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US20080103179A1 (en) * 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
US7674776B2 (en) 1999-06-14 2010-03-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
DE60035870T2 (de) 1999-06-14 2008-05-08 Vivus Inc., Mountain View Kombinationstherapie zur gewichtsreduzierung und fettleibigkeitsbehandlung
US20080255093A1 (en) * 1999-06-14 2008-10-16 Tam Peter Y Compositions and methods for treating obesity and related disorders
US6191117B1 (en) * 2000-07-10 2001-02-20 Walter E. Kozachuk Methods of producing weight loss and treatment of obesity
US6627653B2 (en) 2000-08-02 2003-09-30 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful for the treatment of depression
CA2430010A1 (en) 2000-11-30 2002-06-06 University Of Florida Treatments for neurogenetic disorders, impulse control disorders, and wound healing
JP2005502680A (ja) * 2001-08-30 2005-01-27 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 抗痙攣剤およびアセチルコリンエステラーゼ阻害剤による痴呆および記憶障害の処置
US20040235957A1 (en) * 2001-10-12 2004-11-25 David Bleakman Use of sulfonamide derivatives as pharmaceuticals compounds
US20090088443A1 (en) * 2002-02-15 2009-04-02 Julius Remenar Novel crystalline forms of conazoles and methods of making and using the same
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
US6559293B1 (en) * 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
EP1494998A2 (en) 2002-03-01 2005-01-12 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
US20070059356A1 (en) * 2002-05-31 2007-03-15 Almarsson Oern Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
CA2489984A1 (en) * 2002-06-21 2003-12-31 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
EP1534238A1 (en) * 2002-07-29 2005-06-01 ALZA Corporation Formulations and dosage forms for controlled delivery of topiramate
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US20050070524A1 (en) * 2003-06-06 2005-03-31 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and an anticonvulsant agent for the treatment of central nervous system disorders
AU2004312084A1 (en) * 2003-12-29 2005-07-21 Alza Corporation, Inc. Novel drug compositions and dosage forms of topiramate
TW200612905A (en) * 2004-06-16 2006-05-01 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
MX2007002309A (es) * 2004-08-24 2007-10-08 Johnson & Johnson Novedosos derivados de heteroarilsulfamida benzofusionados utiles como agentes anticonvulsivos.
JP2008545650A (ja) * 2005-05-20 2008-12-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ スルファミド誘導体の製造方法
US8497298B2 (en) * 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US8716231B2 (en) * 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8691867B2 (en) * 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8492431B2 (en) * 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US20070191450A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Mania and Bipolar Disorder
US20070191449A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Depression
US20070191474A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
TW200812573A (en) * 2006-05-19 2008-03-16 Janssen Pharmaceutica Nv Co-therapy for the treatment of epilepsy and related disorders
US9744137B2 (en) * 2006-08-31 2017-08-29 Supernus Pharmaceuticals, Inc. Topiramate compositions and methods of enhancing its bioavailability
WO2008061226A2 (en) 2006-11-17 2008-05-22 Supernus Pharmaceuticals Inc. Sustained-release formulations of topiramate
CN102218044A (zh) 2006-12-04 2011-10-19 苏佩努斯制药公司 托吡酯的增强的立即释放制剂
US20090247616A1 (en) * 2008-03-26 2009-10-01 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
US20090304789A1 (en) 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
US8580298B2 (en) 2008-06-09 2013-11-12 Vivus, Inc. Low dose topiramate/phentermine composition and methods of use thereof
MX2011000090A (es) 2008-06-23 2011-03-02 Janssen Pharmaceutica Nv Forma cristalina de (2s)-(-)-n-(6-cloro-2,3-dihidro-benzo[1,4]diox in-2-ilmetil)sulfamida.
US8815939B2 (en) * 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US20220016074A1 (en) 2018-11-21 2022-01-20 Rosemont Pharmaceuticals Limited Oral topiramate suspension formulations with extended shelf stability and enhanced bioavailability

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US5384327A (en) * 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates

Also Published As

Publication number Publication date
DE69736183T2 (de) 2007-04-26
CA2258895C (en) 2006-06-06
BR9712783A (pt) 2000-10-24
ES2267144T3 (es) 2007-03-01
HUP0003381A3 (en) 2001-12-28
DE69736183D1 (de) 2006-08-03
CN1224350A (zh) 1999-07-28
AU3409697A (en) 1998-01-21
CA2258895A1 (en) 1998-01-08
CZ427798A3 (cs) 1999-08-11
JP2002515875A (ja) 2002-05-28
NO986051L (no) 1999-02-23
ZA975773B (en) 1998-12-28
NO317641B1 (no) 2004-11-29
KR20000022233A (ko) 2000-04-25
EP0932398A1 (en) 1999-08-04
WO1998000123A1 (en) 1998-01-08
CZ297342B6 (cs) 2006-11-15
AU739363B2 (en) 2001-10-11
EP0932398B1 (en) 2006-06-21
RU2185824C2 (ru) 2002-07-27
AP1401A (en) 2005-04-29
US5753693A (en) 1998-05-19
HUP0003381A2 (hu) 2001-05-28
NZ333565A (en) 2000-07-28
IL127714A0 (en) 1999-10-28
AP9801427A0 (en) 1998-12-31
ATE330593T1 (de) 2006-07-15
SK180498A3 (en) 2000-03-13
NO986051D0 (no) 1998-12-22

Similar Documents

Publication Publication Date Title
IL127714A (en) Use of Topiramate or its history for the preparation of a preparation for the treatment of disorders of bipolar manic depression
CA2077637C (en) Compositions comprising a tramadol material and any of codeine, oxycodone or hydrocodone and their use
US4366172A (en) 4-Amino-cyclohexanols, their pharmaceutical compositions and methods of use
US3975532A (en) Hexahydro-1H-furo(3,4-c) pyrrole compounds for treating pain
US4314944A (en) 4-Aminoalkyl-7-hydroxy-2(3H)-indolones
HU214321B (hu) Eljárás tramadol-N-oxid-származék, enantiomerjei és ezeket hatóanyagként tartalmazó gyógyszerkészítmények előállítására
FI93116C (fi) Stereospesifinen menetelmä furo/3,4-c/pyridiini-enantiomeerien valmistamiseksi
US3717641A (en) Derivatives of dibenzo cycloocten-5,11-imine
CA1094071A (en) Trans-5-aryl-2,3,4,4a,5,9b-hexahydro-1h-pyrido[4,3- b] indoles
US4581172A (en) Substituted pyrimido[6,1-a]isoquinolin-4-ones,pyrimido[6,1-a]benzozepin-4-ones and pyrimido[6,1-a]benzodiazepin-4-ones useful for prevention of thromboses and treating hypertension
US3917704A (en) Alpha-aminoalkyl-4-hydroxy-3-alkylsulfonylmethylbenzyl alcohols
GB2297749A (en) 1-[2-(substituted vinyl)]-3,4-dihydro-5H-2,3-benzodiazepine derivatives
FI85142B (fi) Foerfarande foer framstaellning av ergolinestrar.
US5438069A (en) Glucohydrolase inhibitors useful as antidiabetic agents
US3435041A (en) 2-anilinoquinolines
IL108369A (en) Pharmaceuticals for increasing the susceptibility of malignant malignancies containing diarylalkyl piperidines
FI67382B (fi) Foerfarande foer framstaellning av ny kaerlvidgande 10-brom-14-oxo-15-hydroxi-e-homo-eburnan
US4421768A (en) Fluorinated diamino-heptene and-heptyne derivatives
US4250180A (en) Method of treating arrhythmia
US3796715A (en) 8-alkoxy-3,4-dihydroisoquinolines
US3910917A (en) 1-Oxo-hexahydroacridines
US3560620A (en) Induction of fibrinolysis
US4001259A (en) 3,6-diamino-3,4-dihydro-2-pyridones
US4340601A (en) Dopaminergic isoquinolines
US4691051A (en) Adamantyl phenyl β-alanines

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees